首页 / 院系成果 / 成果详情页

Antibody-modified liposomes for tumor-targeting delivery of timosaponin AIII 期刊论文

编号：

5487cc04-b0f9-45b8-9615-89cb85c8e8bd
作者：

Lu, Lu#^[1]Ding, Yue(丁越)*^[2]Zhang, Yong(张勇)^[2]Ho, Rodney J. Y.^[3];Zhao, Yuan(赵源)^[4]Zhang, Tong(张彤)*^[1]Guo, Chunrong(郭春荣)^[2]
语种：

英文
期刊：

INTERNATIONAL JOURNAL OF NANOMEDICINE ISSN：1178-2013 2018 年 13 卷 (1927 - 1944)
收录：
关键词：

timosaponin AIII liposomes CD44 tumor-targeting drug delivery receptor-mediated drug targeting
摘要：

Introduction: Timosaponin AIII (TAIII), as a steroid saponin in Anemarrhena asphodeloides, has favorable potential as an antitumor candidate. However, its hydrophobicity and low bioavailability severely limit its in vivo antitumor efficacy.
Methods: To overcome this drawback, TAIII-loaded liposomes (LP) were prepared to improve TAIII solubility and extend its circulation time. Furthermore, anti-CD44 antibody-modified LP (CD44-LP) was prepared to enhance the therapeutic index of TAIII. The LP and CD44-LP were also characterized through their biological activity, target selective binding and uptake, and in vivo pharmacokinetics.
Results: Compared with free TAIII, both LP and CD44-LP possessed a desirable sustained-release profile in vitro, with similar to 14.2- and 10.7-fold longer TAIII half-life, respectively, and 1.7- and 1.9-fold larger area under the curve, respectively. LP and CD44-LP enhanced TAIII antitumor activity against HepG2 cells and in a xenograft mouse model without detectable toxicity. In particular, CD44-LP exhibited notably higher cytotoxicity than did LP, with a lower half-maximal inhibitory concentration (48 h). CD44-LP exhibited stronger tumor inhibition, and the tumor inhibitory effect was 1.3-fold that of LP. Furthermore, confocal laser scanning microscopy and in vivo near-infrared imaging of a xenograft mouse model revealed that compared with LP, CD44-LP could effectively enhance tumor accumulation.
Conclusion: Taken together, the results indicate that both CD44-LP and LP can considerably extend TAIII circulation time, increase tumor-targeted accumulation, and enhance antitumor activity. Thus, the anti-CD44 antibody-modified liposome is a promising candidate for treating CD44-positive cancer with considerable antitumor effects.
推荐引用方式
GB/T 7714：

Lu Lu,Ding Yue,Zhang Yong, et al. Antibody-modified liposomes for tumor-targeting delivery of timosaponin AIII [J].INTERNATIONAL JOURNAL OF NANOMEDICINE,2018,13:1927-1944.
APA：

Lu Lu,Ding Yue,Zhang Yong,Ho Rodney J. Y.,&Guo Chunrong.(2018).Antibody-modified liposomes for tumor-targeting delivery of timosaponin AIII .INTERNATIONAL JOURNAL OF NANOMEDICINE,13:1927-1944.
MLA：

Lu Lu, et al. "Antibody-modified liposomes for tumor-targeting delivery of timosaponin AIII" .INTERNATIONAL JOURNAL OF NANOMEDICINE 13(2018):1927-1944.
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：54  下载次数：0

分享到：

浏览次数：54

下载次数：0

打印次数：0